Evidence map›Paper›PMID 40824734›Full record

ArticleClinical and translational medicine2025

Sirtuin1 mitigation of calcium oxalate nephropathy via enhancing itaconate abundance through reduction of histone trimethylation.

Xiangyang Yao, Haoran Liu, Chen Duan, Yangjun Zhang, Xiaoliang Wu, Bo Li, Sheng Li, Yan Gong, Tongzu Liu, Xinghuan Wang and 1 more

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xiangyang YaoDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Haoran LiuDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Chen DuanDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Yangjun ZhangDepartment of Urology, The First Affiliated Hospital of University of Science and Technology, Hefei, China.
Xiaoliang WuDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Henan, China.
Bo LiDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Sheng LiDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID 0000-0003-4070-7345
Yan GongTumor Precision Diagnosis and Treatment Technology and Translational Medicine, Hubei Engineering Research Center, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID 0000-0002-4805-0459
Tongzu LiuDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xinghuan WangDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID 0000-0003-3497-0024
Hua XuDepartment of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.ORCID 0009-0008-3100-107X

Funding

Anhui Postdoctoral Science Foundation 2021A482Anhui Provincial Department of Education Research Project KJ2020A0167China Postdoctoral Science Foundation 2021M690185National Natural Science Foundation of China 82070726National Natural Science Foundation of China 82100808National Natural Science Foundation of China 82270803
6 · The paper itself

Abstract

backgroundClinical therapeutic approaches to prevent and treat renal injury in patients with acute kidney injury (AKI) and chronic kidney disease (CKD) induced by calcium oxalate (CaOx) are limited. As a pivotal deacetylase, Sirtuin1 (Sirt1) exhibits notably anti-inflammatory effects, but its metabolic mechanism in regulating CaOx nephropathy remains unexplored.

methodsWe analysed organic acid metabolism in kidney using the nontargeted metabolome and identified key targets by RNA-seq. Evaluate renal injury and oxidative stress using techniques such as Positron Emission Tomography-Computed Tomography (PET/CT) and transmission electron microscope. The protective mechanisms of Sirt1 against CaOx-induced kidney injury and subsequent crystal deposition were demonstrated using in vitro coculture systems and in vivo Sirt1 conditional knockout mice.

resultsWe found that Sirt1 has a significant protective effect on renal injury and oxidative stress induced by CaOx. Sirt1 expression decreases in CaOx nephropathy mice, and activation of Sirt1 reduces CaOx-induced kidney injury and crystal deposition by increasing the level of itaconate. In addition, it was found that Sirt1 enhances immunoresponsive gene 1 and inhibits Sdha by trimethylating histones, thereby regulating the oxidation levels of itaconate and succinate. Furthermore, we emphasise the valuable role of Sirt1 agonists and exogenous itaconate in alleviating crystal induced kidney injury.

conclusionsOur study revealed a previously unknown function of Sirt1 in CaOx nephropathy. By regulating itaconate level through epigenetic, Sirt1 protects against renal inflammation and oxidative damage induced by CaOx. Our preclinical data suggest that targeted Sirt1 agonism represents a promising therapeutic intervention for progressive crystallopathic nephropathy, potentially disrupting the inflammation-crystallisation vicious cycle. HIGHLIGHTS: Sirt1 is significantly reduced in CaOx-induced nephropathy models in vivo and calcium oxalate monohydrate (COM) induced in vitro. Sirt1 in macrophages alleviated CaOx-induced kidney injury and crystal deposition via elevating itaconate levels. Conditional knockout of Sirt1 in vivo significantly exacerbates renal crystal deposition and function damage. We accurately evaluated CaOx-induced renal inflammation status by micro

Indexed as

Calcium OxalateHistonesKidney DiseasesSirtuin 1SuccinatesAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutOxidative StressCalcium OxalateHistonesitaconic acidSirt1 protein, mouseSirtuin 1Succinatescalcium oxalate nephropathyitaconatemacrophageSirt1

Identifiers

PMID40824734
PMCPMC12360365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.